UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the Quarterly Period Ended
August 31, 2001
[_] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the Transition Period From
_______________ to _______________
Commission file number 0-17988
NEOGEN CORPORATION
(Exact name of Registrant as specified in its charter)
Michigan 38-2367843
(State or other jurisdiction of (I.R.S. Employer
corporation or organization) Identification No.)
620 Lesher Place
Lansing, Michigan 48912
(517) 372-9200
(Address of principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes X No
As of October 1, 2001, there were 5,911,000 outstanding shares of Common Stock.
INDEX
NEOGEN CORPORATION AND SUBSIDIARIES
PART I. FINANCIAL INFORMATION
------- ---------------------
ITEM 1. Interim Financial Statements (unaudited)
Consolidated Balance Sheets - August 31, 2001 and May 31, 2001
Consolidated Statements of Operations - Three months ended August 31,
2001 and 2000
Consolidated Statements of Stockholders' Equity - Three months ended
August 31, 2001
Consolidated Statements of Cash Flows - Three months ended August 31,
2001 and 2000
Notes to Interim Consolidated Financial Statements - August 31, 2001
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
PART II. OTHER INFORMATION
-------- -----------------
Item 1. Legal Proceedings
Item 2. Changes in Securities
Item 3. Defaults upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
SIGNATURES
----------
-2-
PART I. FINANCIAL INFORMATION
ITEM 1. Interim Financial Statements
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
NEOGEN CORPORATION AND SUBSIDIARIES
August 31 May 31
2001 2001
----------- -----------
ASSETS
CURRENT ASSETS
Cash $ 699,000 $ 848,000
Marketable securities 3,579,000 6,334,000
Accounts receivable, net 6,112,000 6,026,000
Inventories 6,759,000 6,974,000
Other current assets 1,268,000 1,397,000
----------- -----------
TOTAL CURRENT ASSETS 18,417,000 21,579,000
PROPERTY AND EQUIPMENT, NET 3,167,000 2,721,000
INTANGIBLE AND OTHER ASSETS - NOTE B
Goodwill 11,419,000 7,223,000
Other intangible assets, net 1,258,000 930,000
Other assets 578,000 569,000
----------- -----------
13,255,000 8,722,000
----------- -----------
$34,839,000 $33,022,000
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 1,693,000 $ 1,207,000
Other accrued liabilities 1,324,000 2,079,000
Current maturities of long-term notes payable 49,000 49,000
----------- -----------
TOTAL CURRENT LIABILITIES 3,066,000 3,335,000
LONG-TERM NOTES PAYABLE 16,000 28,000
OTHER LONG-TERM LIABILITIES 322,000 322,000
STOCKHOLDERS' EQUITY
Common stock:
Par value $.16 per share, 20,000,000 950,000 932,000
shares authorized, 5,937,608 shares
issued and outstanding at August 31, 2001;
5,823,520 shares issued and
outstanding at May 31, 2001
Additional paid-in capital 22,778,000 21,560,000
Retained earnings 7,707,000 6,845,000
----------- -----------
31,435,000 29,337,000
----------- -----------
$34,839,000 $33,022,000
=========== ===========
See notes to interim consolidated financial statements
-3-
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
NEOGEN CORPORATION AND SUBSIDIARIES
Three Months Ended August 31
2001 2000
----------------------------
NET SALES $ 9,732,000 $ 8,124,000
Cost of goods sold 4,840,000 4,128,000
----------- -----------
GROSS MARGIN 4,892,000 3,996,000
OPERATING EXPENSES
Sales and marketing 2,147,000 1,847,000
General and administrative 998,000 928,000
Research and development 512,000 419,000
----------- -----------
3,657,000 3,194,000
----------- -----------
OPERATING INCOME 1,235,000 802,000
OTHER INCOME
Interest income 53,000 111,000
Interest expense (1,000) (10,000)
Other 76,000 69,000
----------- -----------
128,000 170,000
----------- -----------
INCOME BEFORE TAXES ON INCOME 1,363,000 972,000
TAXES ON INCOME 501,000 300,000
----------- -----------
NET INCOME $ 862,000 $ 672,000
=========== ===========
NET INCOME PER SHARE:
Basic $ 0.14 $ 0.12
=========== ===========
Diluted $ 0.14 $ 0.12
=========== ===========
See notes to interim consolidated financial statements.
-4-
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)
NEOGEN CORPORATION AND SUBSIDIARIES
Common Stock
------------------------ Additional
Number Paid-In Retained
of Shares Amount Capital Earnings
----------- ----------- ----------- -----------
Balance at June 1, 2001 5,823,520 $ 932,000 $21,560,000 $ 6,845,000
Exercise of options and warrants 20,600 3,000
Acquisitions 93,488 15,000 125,000 1,093,000
Net income for the
three months ended
August 31, 2001 862,000
----------- ----------- ----------- -----------
Balance at August 31, 2001 5,937,608 $ 950,000 $22,778,000 $ 7,707,000
=========== =========== =========== ===========
See notes to interim consolidated financial statements.
-5-
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
NEOGEN CORPORATION AND SUBSIDIARIES
Three Months Ended August 31
2001 2000
----------------------------
OPERATING ACTIVITIES:
Net income $ 862,000 $ 672,000
Adjustments to reconcile net income to net
cash provided from operating activities:
Depreciation and amortization 269,000 332,000
Changes in operating assets and
Liabilities, net of acquisitions:
Accounts receivable 223,000 (494,000)
Inventories 344,000 6,000
Other current assets 129,000 (175,000)
Accounts payable 249,000 132,000
Other accrued expenses (754,000) (439,000)
----------- -----------
NET CASH PROVIDED BY
OPERATING ACTIVITIES 1,322,000 34,000
INVESTING ACTIVITIES:
Sales of marketable securities 8,142,000 3,212,000
Purchases of marketable securities (5,386,000) (87,000)
Purchases of property and equipment
and other assets (756,000) (298,000)
Acquisitions (3,587,000) (3,334,000)
----------- -----------
NET CASH USED IN
INVESTING ACTIVITIES (1,587,000) (517,000)
FINANCING ACTIVITIES:
Payments on long-term borrowings (12,000) (12,000)
Net proceeds from the issuance
of common stock 128,000 --
Repurchase of common stock -- (544,000)
----------- -----------
NET CASH PROVIDED
BY (USED IN)
FINANCING ACTIVITIES 116,000 (556,000)
----------- -----------
DECREASE IN CASH (149,000) (1,029,000)
Cash at beginning of period 848,000 2,198,000
----------- -----------
CASH AT END OF PERIOD $ 699,000 $ 1,169,000
=========== ===========
See notes to interim consolidated financial statements.
-6-
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NEOGEN CORPORATION AND SUBSIDIARIES
NOTE A - BASIS OF PRESENTATION
------------------------------
The accompanying unaudited condensed financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting only of
normal recurring accruals) considered necessary for a fair presentation have
been included. The results of operations for the three months ended August 31,
2001 are not necessarily indicative of the results to be expected for the fiscal
year ending May 31, 2002. For more complete financial information, these
consolidated financial statements should be read in conjunction with the May 31,
2001 audited consolidated financial statements and the notes thereto included in
the Company's annual report on Form 10-K for the year ended May 31, 2001.
NOTE B - CHANGE IN ACCOUNTING FOR GOODWILL
------------------------------------------
The Company has adopted Financial Accounting Standards Board SFAS 142 "Goodwill
and other intangible assets" effective June 1, 2001. Under the provisions of the
Statement, goodwill is no longer amortized but instead is reviewed for
impairment at least annually. In connection with the adoption of the Statement,
Management is required to perform an impairment assessment within six months of
adoption. As of August 31, 2001 the Company had not yet completed the goodwill
impairment review, and therefore has made no determination of any impairment
charges that could result from adoption of this statement.
A reconciliation of the allocation of intangible assets as reported at May 31,
2001 and at June 1, 2001, following the adoption of SFAS 142, is as follows:
May 31, 2001 Reclassifications June 1, 2001
Gross Gross Gross
Carrying Accumulated Carrying Accumulated Carrying Accumulated
Amount Amortization Amount Amortization Amount Amortization
----------- ------------ ----------- ------------ ----------- ------------
Goodwill $ 8,123,000 $ 1,047,000 $ 280,000 $ 133,000 $ 8,403,000 $1,180,000
Intangible assets with
indefinite lives 614,000 199,000 614,000 199,000
Intangible assets with
finite lives 1,019,000 504,000 1,019,000 504,000
Other assets 2,482,000 836,000 (1,913,000) (836,000) 569,000 --
----------- --------------- ----------- ---------- ----------- ----------
$10,605,000 $ 1,883,000 $ -- $ -- $10,605,000 $1,883,000
=========== =========== =========== ========== =========== ==========
-7-
The allocation of assets following SFAS 142 as of June 1, 2001 and
August 31, 2001 is summarized in the following table:
June 1, 2001 August 31, 2001
Gross Gross
Carrying Accumulated Carrying Accumulated
Amount Amortization Amount Amortization
---------- ------------ ----------- ------------
Goodwill:
Food Safety $ 841,000 $ 123,000 $ 4,364,000 $ 123,000
Animal Safety 7,562,000 1,057,000 8,235,000 1,057,000
---------- ---------- ----------- ----------
Total 8,403,000 1,180,000 12,599,000 1,180,000
Intangible assets with indefinite lives 614,000 199,000 614,000 199,000
Intangible assets with finite lives:
Licenses 305,000 69,000 633,000 102,000
Covenants not to compete 355,000 171,000 415,000 186,000
Patents 351,000 263,000 351,000 265,000
Other 8,000 1,000 8,000 1,000
---------- ---------- ----------- ----------
1,019,000 504,000 1,407,000 550,000
As provided by SFAS 142, the results of operations of the quarter ended
August 31, 2000 have not been restated. If the statement had been
adopted as of June 1, 2000, the effect would have resulted in the
reduction in amortization of $92,000; net income of $733,000 and net
income per share of $.13 (basic and diluted).
Estimated fiscal year amortization expense is as follow: 2002-$144,000;
2003-$139,000; 2004-$119,000; 2005-$80,000 and 2006-$53,000.
NOTE C - CHANGE IN ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
-------------------------------------------------------------------------------
SFAS 133, as amended by SFAS 137 and SFAS 138, established accounting
and reporting standards for derivative instruments and for hedging
activities. The Company adopted SFAS 133 as amended, effective June 1,
2001. The adoption of SFAS 133 will not have a significant impact on
the financial position or results of operations of the company because
the Company currently has no derivative instruments or hedging
activities.
-8-
NOTE D - EARNINGS PER SHARE
---------------------------
The following table summarizes the calculation of earnings per share:
Three months
Ended August 31
2001 2000
---------- ----------
Basic and Diluted - Earnings per Share
Numerator - Net Income $ 862,000 $ 672,000
========== ==========
Denominator:
For basic earnings per share-
Weighted average shares 5,950,000 5,731,000
Effect of dilutive securities-
Stock options and warrants 322,000 10,000
---------- ----------
For diluted earnings
per share - adjusted weighted
average shares and assumed conversions 6,272,000 5,741,000
========== ==========
Basic Earnings per Share $ 0.14 $ 0.12
========== ==========
Diluted Earnings per Share $ 0.14 $ 0.12
========== ==========
NOTE E - STOCK REPURCHASE
-------------------------
The Company's board of directors has authorized the purchase of up to 1,000,000
shares of the Company's Common Stock. As of August 31, 2001, the Company had
purchased 626,990 shares (none in the quarter ended August 31, 2001) in
negotiated and open market transactions. Shares purchased under this buy-back
program will be retired and used to satisfy future issuance of Common Stock upon
the exercise of outstanding stock options and warrants.
NOTE F - INVENTORIES
--------------------
Inventories are stated at the lower of cost, determined on the first-in,
first-out method, or market. The components of inventories are as follows:
August 31, 2001 May 31, 2001
--------------- ------------
Raw Material $2,076,000 $1,832,000
Work-In-Process 864,000 885,000
Finished Goods 3,819,000 4,257,000
---------- ----------
$6,759,000 $6,974,000
========== ==========
-9-
NOTE G - SEGMENT INFORMATION
----------------------------
The Company has two reportable segments: Food Safety and Animal Safety. The Food
Safety segment produces and markets diagnostic test kits and related products
used by food producers and processors to detect harmful natural toxins, drug
residues, foodborne bacteria, food allergens, pesticide residues, disease
infections and levels of general sanitation. The Animal Safety segment is
primarily engaged in the production and marketing of products dedicated to
animal health, including 250 different veterinary instruments and a complete
line of consumable products marketed to veterinarians and distributors serving
the professional animal care industry.
These segments are managed separately because they represent strategic business
units that offer different products and require different marketing strategies.
The Company evaluates performance based on total sales and operating income of
the respective segments. Segment information for the three months ended August
31, 2001 and 2000 was as follows:
Food Animal Corporate and
Safety Safety Eliminations (1) Total
--------------------------------------------------------------------------------------------------------
2001
Net sales from external customers $ 4,949,000 $ 4,783,000 $ -- $ 9,732,000
Operating income (loss) 906,000 545,000 (216,000) 1,235,000
Total assets 14,647,000 16,230,000 3,962,000 34,839,000
--------------------------------------------------------------------------------------------------------
2000
Net sales from external customers $ 4,389,000 $ 3,735,000 $ -- $ 8,124,000
Operating income (loss) 692,000 289,000 (179,000) 802,000
Total assets 10,431,000 13,179,000 5,327,000 28,937,000
--------------------------------------------------------------------------------------------------------
(1) Includes corporate assets, consisting principally of marketable
securities, and overhead expenses not allocated to specific business
segments. Also includes the elimination of intersegment transactions
and minority interests.
NOTE H - ACQUISITIONS
---------------------
As of June 30, 2001, the Company purchased 100% of the common stock of QA Life
Sciences. QA has a product line directed toward testing of food and water. The
purchase price, subject to certain post closing adjustments, was 58,000 shares
of Neogen stock with provision for payment of up to an additional 3,100 issued
shares of Neogen stock based on post closing collections of accounts receivable
and an additional $200,000 based on achievement of specific levels of post
closing revenues. The accounts receivable secondary payment requirements were
met and required share payment was made as of August 31, 2001. The purchase
price and acquisition costs were allocated $129,000 to current assets, $150,000
to the property and equipment and $487,000 to intangible assets. Revenues of QA
Life Sciences in the 12 months prior to the acquisition were less than
$1,000,000.
-10-
As of August 1, 2001, the Company purchased for cash substantially all of the
assets of Gene-Trak Systems from Vysis, Inc. Gene-Trak has a product line for
tests of specific bacteria in food. The purchase price and acquisition costs
were allocated $378,000 to current assets, $125,000 to property and equipment
and $3,144,000 to intangible assets. Revenues of Gene-Trak in the 12 months
prior to the acquisition were approximately $3,000,000.
During the quarter, final determination was made of amounts due as secondary
payments to the former owners of AmVet Pharmaceuticals. To satisfy these
obligations, 32,388 shares of Neogen stock valued at $416,000 were issued and
cash payments of $133,000 were made.
These transactions were accounted for as purchases under the provision of SFAS
141. Results of operations are included in the consolidated financial statements
beginning with the date of the acquisition. Common Stock was valued at the
closing price on the date of the transaction after allowance for restriction
related to the shares tendered.
NOTE I - LEGAL PROCEEDINGS
--------------------------
The Company is involved in certain legal proceedings, none of which, in the
opinion of Management is material to the financial statements.
NOTE J - SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION
----------------------------------------------------------
Cash paid for income taxes totaled $1,200,000 and $876,000 in the first quarter
of 2002 and 2001, respectively. Cash paid for interest totaled $1,000 and
$11,000 in 2002 and 2001, respectively.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The information in this Management's Discussion and Analysis of Financial
Condition and Results of Operations contains both historical financial
information and forward-looking statements. Neogen does not provide forecasts of
future performance. While management is optimistic about the Company's long-term
prospects, historical financial information may not be indicative of future
financial performance.
The words "anticipate", "believe", "potential", "expect", and similar
expressions used herein are intended to identify forward-looking statements.
Forward-looking statements involve certain risks and uncertainties. Various
factors, including competition, recruitment and dependence on key employees,
impact of weather on agriculture and food production, identification and
integration of acquisitions, research and development risks, patent and trade
secret protection, government regulation and other risks detailed from time to
time in the Company's reports on file at the Securities and Exchange Commission
may cause actual results to differ materially from those contained in the
forward-looking statements.
-11-
Accounting Changes
------------------
In July 2001, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards ("SFAS") 142 "Goodwill and Other Intangible
Assets." As allowed under the Standard, the Company has adopted SFAS 142 as of
June 1, 2001. SFAS 142 requires goodwill and intangible assets with indefinite
useful lives to no longer be amortized, but instead be tested for impairment at
least annually.
With the adoption of SFAS 142, Management reviewed classifications, useful
lives, and residual lives of all acquired intangible assets. Following this
review, changes in classification were made as described in Note B. No changes
in the amortization periods or residual values were determined to be necessary.
SFAS 142 provides a six-month transitional period from the effective date of
adoption for Management to perform an assessment of whether there is an
indication that goodwill is impaired. To the extent that an indication of
impairment exists, Management must perform a second test to measure the amount
of impairment. The second test must be performed as soon as possible, but no
later than the end of the year. Any impairment measured as of the date of
adoption will be recognized as of the cumulative effect of a change in
accounting principle, Management has not determined whether there is any
indication that goodwill is impaired or estimated the amount of any potential
impairment.
Additionally, the Company adopted the provisions of SFAS 133, as amended, as of
June 1, 2001. This statement, which establishes accounting and reporting
standards for derivative instruments and for hedging activities, will not have a
significant impact on the financial position or results of operations of the
Company.
-12-
Three Months Ended August 31, 2001 Compared to Three Months Ended August 31,
----------------------------------------------------------------------------
2000.
-----
Total sales for the quarter ended August 31, 2001 increased $1,608,000 or 19.8%
compared to the same quarter in 2000. Sales of products dedicated to food safety
were up 12.8% and sales of animal safety products were up 28.1%.
The increase in food safety sales came from increases in sales of test kits to
detect harmful bacteria, such as E. coli O157:H7, Salmonella and Listeria, that
increased 23% compared to the prior year as the Company continues to add sales
in this growing market. Additionally, sales of test kits for allergens were up
51%.
The increase in animal safety sales came from a $380,000 increase in sales of
the Triple Crown product line and a $350,000 increase in sales of botulism B
products. Botulism B sales were particularly low in 2000 as a result of supply
problems at that time. Triple Crown sales increases came principally from the
Company's products for wound management which have been a focus product for the
past year and have shown consistently high levels of growth.
Revenues of QA Life Sciences and Gene-Trak Systems that were acquired during the
quarter represented less than 4% of total revenues for the quarter.
Gross margins increased from 49.2% in 2000 to 50.3% in 2001. This change in
margins resulted principally from the effect of changes in product sales mix.
Sales and marketing expenses increased $300,000 or 16.2% from the first quarter
on 2000. These expenses rose in relation to sales increases, however, sales and
marketing costs as a percentage of sales decreased from 22.7% to 22.1%.
General and administrative expenses increased $70,000 or 7.5% from the 2000
quarter. As a percentage of revenue these costs decreased from 11.4% to 10.3%.
The increase in dollar costs consisted principally of personnel additions and
similar costs necessary to provide administrative functions for the
significantly greater level of sales, net of the effect on amortization
following adoption of SFAS 142 as of June 1, 2001.
Research and development expenses increased 22.2% from the 2000 quarter. As a
percentage of revenues, research and development expenses increased from 5.2% to
5.3%. The absolute dollar amount of research and development expense increased
$93,000 from the amount incurred in the comparable quarter of the prior year.
Management intends to maintain research and development expenditures for product
lines that require such expenditures at 8% to 10% of revenues.
Interest income decreased in the 2001 quarter as a result of the reduction in
invested balances following the purchase of QA Life Sciences and Gene-Trak
Systems and decrease in rates.
The federal and state tax rate in the first quarter of 2001 increased to 36.8%
of income before taxes on income from 30.9% in the prior year. The tax provision
in the prior year was favorably affected by certain tax credits carried forward
from earlier years. No further credit carryovers are available.
These increases were offset by a reduction in amortization expense for
intangible assets of $92,000 as the result of the adoption of SFAS 142 as of
June 1, 2001.
-13-
Financial Condition and Liquidity
---------------------------------
At August 31, 2001, the Company had $4,278,000 in cash and marketable
securities, working capital of $15,351,000 and stockholders' equity of
$31,435,000. In addition, the Company has bank lines of credit totaling
$10,000,000 with no borrowings against these lines. Cash and marketable
securities decreased during the first quarter with cash provided by operating
activities offset by $4,300,000 of cash expended for acquisitions, including
Gene-Trak Systems, and property and equipment.
Inclusive of the effect of acquisitions, accounts receivable increased $86,000
and inventories decreased $215,000 at August 31, 2001 compared to May 31. This
resulted from continued strong management of these assets despite the effect of
the acquisitions and the increase in the level of operations. The decrease in
current liabilities result from timing of payments, principally those related to
federal income taxes.
At August 31, 2001, the Company had no material commitments for capital
expenditures. Inflation and changing prices are not expected to have a material
effect on the Company's operations.
Management believes that the Company's existing cash and marketable securities
at August 31, 2001, along with its available bank lines of credit and cash
expected to be generated from future operations, will be sufficient to fund
activities for the foreseeable future. However, existing cash and marketable
securities may not be sufficient to meet the Company's cash requirements to
commercialize products currently under development or its plans to acquire
additional technology and products that fit within the Company's mission
statement. Accordingly, the Company may be required to issue equity securities
or enter into other financing arrangements for a portion of the Company's future
capital needs.
-14-
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
-----------------
The Company is involved in certain legal proceedings, none of which, in the
opinion of the management is material to the financial statements.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
--------------------------------
(a) Exhibit Index
-------------
Exhibit 10.1 - Asset Purchase Agreement between registrant and Vysis, Inc. dated
August 4, 2001.
(b) Reports on Form 8-K Filed in Quarterly Period Ended August 31, 2001.
--------------------------------------------------------------------
The Company filed a report on August 10, 2001 on Form 8-K reporting the
acquisition of Gene-Trak Systems.
-15-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NEOGEN CORPORATION
10/12/01 /s/ James L. Herbert
---------------- -----------------------------------
Date James L. Herbert
President
10/12/01 /s/ Richard R. Current
----------------- -----------------------------------
Date Richard R. Current
Vice President & Chief
Financial Officer
-16-
EXHIBIT INDEX
-------------
EXHIBIT NO. DESCRIPTION
----------- -----------
10.1 ASSET PURCHASE AGREEMENT BETWEEN REGISTRANT AND
VYSIS, INC. DATED AUGUST 4, 2001.
-17-